In silico analysis of pathways affected by differentially expressed microRNA in adrenocortical tumors

Journal of Endocrinological Investigation

Volumn 36, Issue 11, 2013, Pages 1011-1019

  Zsippai, A ^a   Szabo P M ^b   Szabo D R ^a   Nagy, Z ^a   Patocs A ^b   Racz K ^a   Igaz, P ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

Adrenocortical tumor; microRNA; mRNA targets; Pathways

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; CYCLINE; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; INTEGRIN; INTERLEUKIN 1; MICRORNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; RETINOIC ACID; RETINOID X RECEPTOR ALPHA;

ADRENAL CORTEX ADENOMA; ARTICLE; BIOINFORMATICS; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE REGULATION; CHROMOSOME REPLICATION; COMPUTER MODEL; DNA DAMAGE; DRUG TARGETING; FUNCTIONAL GENOMICS; SIGNAL TRANSDUCTION;

ADRENAL CORTEX NEOPLASMS; CELL CYCLE; COMPUTATIONAL BIOLOGY; DATABASES, GENETIC; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; METABOLIC NETWORKS AND PATHWAYS; MICRORNAS; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRETINOIN; UP-REGULATION;

EID: 84891674597     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.3275/9024     Document Type: Article

References (53)

1. Koch CA, Pacak K, Chrousos GP. The molecular pathogenesis of hereditary and sporadic adrenocortical and adrenomedullary tumors. J Clin Endocrinol Metab 2002, 87: 5367-84.
2. Soon PS, McDonald KL, Robinson BG, Sidhu SB. Molecular markers and the pathogenesis of adrenocortical cancer. Oncologist 2008, 13: 548-61.
3. Fassnacht M, Libé R, Kroiss M, Allolio B. Adrenocortical carcinoma: a clinician's update. Nat Rev Endocrinol 2011, 7: 323-35.
4. Stahlhut Espinosa CE, Slack FJ. The role of microRNAs in cancer. Yale J Biol Med 2006, 79: 131-40.
5. Baek D, Villén J, Shin C, Camargo FD, Gygi SP, Bartel DP. The impact of microRNAs on protein output. Nature 2008, 455: 64-71.
6. Selbach M, Schwanhäusser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N. Widespread changes in protein synthesis induced by microRNAs. Nature 2008, 455: 58-63.
7. Lionetti M, Agnelli L, Lombardi L, Tassone P, Neri A. MicroRNAs in the pathobiology of multiple myeloma. Curr Cancer Drug Targets 2012, 12: 823-37.
8. Lee RC, Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. Science 2001, 294: 862-64.
9. Chen CZ. MicroRNAs as oncogenes and tumor suppressors. N Engl J Med 2005, 353: 1768-71.
10. Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A 2005, 102: 13944-9.
11. Vreugdenhil E, Verissimo CS, Mariman R, et al. MicroRNA 18 and 124a down-regulate the glucocorticoid receptor: implications for glucocorticoid responsiveness in the brain. Endocrinology 2009, 150: 2220-8.
12. Ventura A, Jacks T. MicroRNAs and cancer: short RNAs go a long way. Cell 2009, 136: 586-91.
13. Wijnhoven BP, Michael MZ, Watson DI. MicroRNAs and cancer. Br J Surg 2007, 94: 23-30.
14. Bottoni A, Zatelli MC, Ferracin M, et al. Identification of differentially expressed microRNAs by microarray: a possible role for microRNA genes in pituitary adenomas. J Cell Physiol 2007, 210: 370-7.
15. Roldo C, Missiaglia E, Hagan JP, et al. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol 2006, 24: 4677-84.
16. Weber F, Teresi RE, Broelsch CE, Frilling A, Eng C. A limited set of human MicroRNA is deregulated in follicular thyroid carcinoma. J Clin Endocrinol Metab 2006, 91: 3584-91.
17. Tömböl Z, Szabó PM, Molnár V, et al. Integrative molecular bioinformatics study of human adrenocortical tumors: microRNA, tissue-specific target prediction, and pathway analysis. Endocr Relat Cancer 2009, 16: 895-906.
18. Soon PS, Tacon LJ, Gill AJ, et al. miR-195 and miR-483-5p Identified as Predictors of Poor Prognosis in Adrenocortical Cancer. Clin Cancer Res 2009, 15: 7684-92.
19. Patterson EE, Holloway AK, Weng J, Fojo T, Kebebew E. MicroRNA profiling of adrenocortical tumors reveals miR-483 as a marker of malignancy. Cancer 2011, 117: 1630-9.
20. Schmitz KJ, Helwig J, Bertram S, et al. Differential expression of microRNA-675, microRNA-139-3p and microRNA-335 in benign and malignant adrenocortical tumours. J Clin Pathol 2011, 64: 529-35.
21. Özata DM, Caramuta S, Velázquez-Fernández D, et al. The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma. Endocr Relat Cancer 2011, 18: 643-55.
22. Singh P, Soon PS, Feige JJ, et al. Dysregulation of microRNAs in adrenocortical tumors. Mol Cell Endocrinol 2012, 351: 118-28.
23. Szabó PM, Butz H, Igaz P, Rácz K, Hunyady L, Patócs A. Including microRNAs into "omics"-based networks: a potential novel approach for modeling endocrine diseases (MiRomics in endocrinology). Mol Endocrinol 2013, 27: 573-85.
24. de Reyniès A, Assié G, Rickman DS, et al. Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J Clin Oncol 2009, 27: 1108-15.
25. Giordano TJ, Kuick R, Else T, et al. Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin Cancer Res 2009, 15: 668-76.
26. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genomewide expression profiles. Proceedings of the National Academy of Sciences USA 2005, 102: 15545-50.
27. Szabó PM, Tamási V, Molnár V, et al. Meta-analysis of adrenocortical tumour genomics data: novel pathogenic pathways revealed. Oncogene 2010, 29: 3163-72.
28. Wen X, Li Y, Hu K, Dai C, Liu Y. Hepatocyte growth factor receptor signaling mediates the anti-fibrotic action of 9-cis-retinoic acid in glomerular mesangial cells. Am J Pathol 2005, 167: 947-57.
29. Ferré P. The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes 2004, 53 (Suppl 1): 43-50.
30. Betz MJ, Shapiro I, Fassnacht M, Hahner S, Reincke M, Beuschlein F. Peroxisome proliferator-activated receptor-γ agonists suppress adrenocortical tumor cell proliferation and induce differentiation. J Clin Endocrinol Metab 2005, 90: 3886-96.
31. Ferruzzi P, Ceni E, Tarocchi M, et al. Thiazolidinediones inhibit growth and invasiveness of the human adrenocortical cancer cell line H295R. J Clin Endocrinol Metab 2005, 90: 1332-9.
32. Chen Y, Stallings RL. Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. Cancer Res 2007, 67: 976-83.
33. Saumet A, Vetter G, Bouttier M, et al. Estrogen and retinoic acid antagonistically regulate several microRNA genes to control aerobic glycolysis in breast cancer cells. Mol Biosyst 2012, 8: 3242-53.
34. Zhao JJ, Yang J, Lin J, et al. Identification of miRNAs associated with tumorigenesis of retinoblastoma by miRNA microarray analysis. Childs Nerv Syst 2009, 25: 13-20.
35. Tong JL, Zhang CP, Nie F, et al. MicroRNA 506 regulates expression of PPAR alpha in hydroxycamptothecin-resistant human colon cancer cells. FEBS Lett 2011, 585: 3560-8.
36. Romao JM, Jin W, Dodson MV, Hausman GJ, Moore SS, Guan LL. MicroRNA regulation in mammalian adipogenesis. Exp Biol Med 2011, 236: 997-1004.
37. Kent OA, Mullendore M, Wentzel EA, et al. A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells. Cancer Biol Ther 2009, 8: 2013-24.
38. Rachagani S, Kumar S, Batra SK. MicroRNA in pancreatic cancer: pathological, diagnostic and therapeutic implications. Cancer Lett 2010, 292: 8-16.
39. Garzon R, Pichiorri F, Palumbo T, et al. MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia. Oncogene 2007, 26: 4148-57.
40. Puga A, Marlowe J, Barnes S, et al. Role of the aryl hydrocarbon receptor in cell cycle regulation. Toxicology 2002, 182: 171-7.
41. Barouki R, Coumoul X, Fernandez-Salguero PM. The aryl hydrocarbon receptor, more than a xenobiotic-interacting protein. FEBS Lett 2007, 581: 3608-15.
42. Liebermann DA, Tront JS, Sha X, et al. Gadd45 stress sensors in malignancy and leukemia. Crit Rev Oncog 2011, 16: 129-40.
43. Augoff K, Das M, Bialkowska K, McCue B, Plow EF, Sossey-Alaoui K. miR-31 is a broad regulator of β1-integrin expression and function in cancer cells. Mol Cancer Res 2011, 9: 1500-8.
44. Penna E, Orso F, Cimino D, et al. microRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C. EMBO J 2011, 30: 1990-2007.
45. Oneyama C, Morii E, Okuzaki D, et al. MicroRNA-mediated upregulation of integrin-linked kinase promotes Src-induced tumor progression. Oncogene 2012, 31: 1623-35.
46. Huang L, Luo J, Cai Q, et al. MicroRNA-125b suppresses the development of bladder cancer by targeting E2F3. Int J Cancer 2011, 128: 1758-69.
47. Legesse-Miller A, Elemento O, Pfau SJ, Forman JJ, Tavazoie S, Coller HA. let-7 overexpression leads to an increased fraction of cells in G2/M, direct down-regulation of Cdc34, and stabilization of Wee1 kinase in primary fibroblasts. J Biol Chem 2009, 284: 6605-9.
48. Liu C, Kelnar K, Vlassov AV, Brown D, Wang J, Tang DG. Distinct microRNA expression profiles in prostate cancer stem/progenitor cells and tumor-suppressive functions of let-7. Cancer Res 2012, 72: 3393-404.
49. Jia HY, Wang YX, Yan WT, et al. MicroRNA-125b Functions as a Tumor Suppressor in Hepatocellular Carcinoma Cells. Int J Mol Sci 2012, 13: 8762-74.
50. Zhang Y, Yan LX, Wu QN, et al. miR-125b is methylated and functions as a tumor suppressor by regulating the ETS1 proto-oncogene in human invasive breast cancer. Cancer Res 2011, 71: 3552-62.
51. Lin KY, Zhang XJ, Feng DD, et al. miR-125b, a target of CDX2, regulates cell differentiation through repression of the core binding factor in hematopoietic malignancies. J Biol Chem 2011, 286: 38253-63.
52. Duan Z, Choy E, Harmon D, et al. MicroRNA-199a-3p is downregulated in human osteosarcoma and regulates cell proliferation and migration. Mol Cancer Ther 2011, 10: 1337-45.
53. Shen L, Li J, Xu L, et al. miR-497 induces apoptosis of breast cancer cells by targeting Bcl-w. Exp Ther Med 2012, 3: 475-80.